A Study to Evaluate the Safety and Pharmacokinetics of AG2304 Compared to Coadministration of AG23041 and AG23042

An Open-label, Randomized, Fasting, Single, Group 2, Stage 2, Cross-over Study to Evaluate the Safety and Pharmacokinetics of AG2304 Compared to Coadministration of AG23041 and AG23042 in Healthy Adult Volunteers

The objective of this study is to evaluate the pharmacokinetic characteristics of AG2304 in healthy subjects.

To evaluate the pharmacokinetic characteristics and safety profiles of AG2304 compared with coadministration AG23041 and AG23042 after a single oral dose administration in healthy Korean subjects under fasting conditions.

Inclusion Criteria:

• A healthy adults aged 19-65 years at the time of screening
• Subjects who are deemed eligible based on the screening tests

Exclusion Criteria:

• Subjects who have taken the investigational drug within 6 months prior to the first dose
• Other exclusions have been applied